IP Library › Granted Patent US 12,508,243
Granted Patent B2
US 12,508,243 · App. 17/789,044 · Granted Dec 30, 2025

Compositions and methods for treating cancer and improving epithelial homeostasis

Inventors: Brigitte N. Gomperts (Los Angeles, CA); Cody J. Aros (Los Angeles, CA)
Assignee: The Regents of the University of California
A61K31/352A61K31/404A61K31/496A61K31/5377A61P11/00A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,243
App. No.
17/789,044
Granted
Dec 30, 2025
Kind
B2
Abstract

The present disclosure relates to compositions for use in the treatment of certain disorders (e.g., cancer). The present disclosure also provides methods of treating cancer and/or promoting airway homeostasis.

Claims (26)

1 . A method of

treating squamous lung cancer

in a subject comprising administering to the subject a compound selected from

 or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the method inhibits ABSC hyperproliferation.

3 . The method of claim 1 , wherein the compound is administered by pulmonary administration.

4 . The method of claim 1 , wherein prior to the administration of the compound, the subject has suffered an airway injury.

5 . The method of claim 4 , wherein the subject suffered the injury 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months prior to administration of the compound.

6 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2022
From: GOMPERTS, BRIGITTE N.; AROS, CODY J.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 061330/0275 →
Continuity (2)
Provisional Application 62953260 · Dec 24, 2019
Related Publication 20230092441A1 · Mar 23, 2023
References Cited (47)
EP 2902388A1 · 2015 [cited by applicant]
KR 20200055867A · 2020 [cited by applicant]
WO WO2009060215A1 · 2009 [cited by applicant]
WO WO2009089508A1 · 2009 [cited by applicant]
WO WO2017001733A1 · 2017 [cited by applicant]
WO WO2018223023A1 · 2018 [cited by applicant]
WO WO2020130120A1 · 2020 [cited by applicant]
WO WO2021133460A1 · 2021 [cited by applicant]
Betts et al., Anatomy and Physiology, Ch. 4.2 Epithelial Tissue, OpenStax, Houston, TX., Apr. 25, 2013 (Year: 2013). [cited by examiner]
Youngson, R.M., “Lung Cancer.” The Royal Society of Medicine Health Encyclopedia, 2nd ed., Bloomsbury, published 2000, retrieved from Credo Reference, https://search.credoreference.com/articles/Qm9va0FydGljbGU6MTU1MDMzO… [cited by examiner]
Henderson et al., PNAS, 2010, 107(32), 14309-14314 (Year: 2010). [cited by examiner]
Hynds R.E. & Janes S.M., Cancer Prev. Res., 2017, 10(9), 491-493 (Year: 2017). [cited by examiner]
Kim, Y., Journal of Thoracic Oncology, 2016, 11(12), 2193-2201 (Year: 2016). [cited by examiner]
Ooi et al., Cancer Res., 2010, 70(16), 6639-6648 (Year: 2010). [cited by examiner]
Goel et al., International Journal of Pharmaceutical Investigation, 2013, 3(1), 8-14 (Year: 2013). [cited by examiner]
Areias et al., “New chromene scaffolds for adenosine A2A receptors: Synthesis, pharmacology and structure-activity relationships,” Eur J Med Chem, 54: 303-310 (2012). [cited by applicant]
Aros et al., “High-throughput drug screening identifies a potent Wnt inhibitor that promotes airway basal stem cell homeostasis,” Cell Reports D, 1-18 (Nov. 5, 2019). [cited by applicant]
Asadipour et al., “Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors,” Eur J Med Chem, 70: 623-630 (2013). [cited by applicant]
Bastakoty et al., “Inhibition of Wnt/ß-catenin pathway promotes regenerative repair of cutaneous and cartilage injury,” J FASEB, 29(12): 4881-4892 (2015). [cited by applicant]
Bastakoty et al., “Wnt/ß-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration,” J FASEB, 30(10): 3271-3284 (2016). [cited by applicant]
Bi et al., “Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt/ß-catenin signaling inhibition,” European Journal of Pharmacology, 742: 145-152 (2014). [cited by applicant]
Bujak et al., “Discovery of TRAF-2 and NCK-interacting kinase (TNIK) inhibitors by ligand-based virtual screening methods,” MedChemComm, 6(8): 1564-1572 (2015). [cited by applicant]
Cheng et al., “Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer,” Biomedicine & Pharmacotherapy, 110:473-481 (2019). [cited by applicant]
Emami et al., “A small molecule inhibitor of ß-catenin/CREB-binding protein transcription,” PNAS, 101(34): 12682-12687 (2004). [cited by applicant]
Fujii et al., “An antagonist of dishevelled protein-protein interaction suppresses ß-catenin—dependent tumor cell growth,” Cancer Res, 67(2): 573-579 (2007). [cited by applicant]
Giangreco et al., “ß-Catenin determines upper airway progenitor cell fate and preinvasive squamous lung cancer progression by modulating epithelial-mesenchymal transition,” J Pathol, 226(4): 575-587 (2012). [cited by applicant]
Harb et al., “Recent development of Wnt signaling pathway inhibitors for cancer therapeutics,” Current Oncology Reports, 21(2): 12 (2019). [cited by applicant]
Hu et al., “The role of the Wnt/ß-catenin-Annexin A1 pathway in the process of sevoflurane-induced cognitive dysfunction,” J Neurochem, 137(2): 240-252 (2016). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/057332 mailed Feb. 17, 2021. [cited by applicant]
Kempen et al., “6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis,” Eur J Med Chem, 43(12): 2735-2750 (2008). [cited by applicant]
Korolkov et al., “Synthesis of substituted coumarins and their carborane derivatives as potencial anticancer drugs,” Chemical Journal of Kazakhstan, 2(66): 219-229 (2019). [cited by applicant]
Lafyatis et al., “Inhibition of ß-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82,” JInvestDermatol, 137(12): 2473-2483 (2… [cited by applicant]
Lu., “EGFR and WNT/ß-catenin signalling in airway homeostasis and repair,” Doctoral Dissertation, University College London (168 pages) (2011). [cited by applicant]
Lynch et al., “Wnt signaling regulates airway epithelial stem cells in adult murine submucosal glands,” Stem Cells, 34(11): 2758-2771 (2016). [cited by applicant]
Malleske et al., “Regulation of Human Airway Epithelial Tissue Stem Cell Differentiation by ß-Catenin, P300, and CBP,” Stem Cells, 36(12): 1905-1916 (2018). [cited by applicant]
PubChem CID: 3975636; IUPAC Name: N-butyl-8-methoxy-2-oxochromene-3-carboxamide; Create date: Sep. 12, 2005; National Center for Biotechnology Information. Retrieved from URL: <https://pubchem.ncbi.nlm.nih.gov/compound/… [cited by applicant]
PubChem CID: 43816620; IUPAC Name: 8-methoxy-N-[2-(5-methylfuran-2-yl)phenyl]-2-oxochromene-3-carboxamide; Create date: Jul. 21, 2009; National Center for Biotechnology Information. Retrieved from URL: <https://pubchem.… [cited by applicant]
PubChem CID: 754821; IUPAC Name: 8-methoxy-2-oxo-N-phenylchromene-3-carboxamide; Create date: Jul. 8, 2005; National Center for Biotechnology Information. Retrieved from URL: <https://pubchem.ncbi.nlm.nih.gov/compound/7… [cited by applicant]
Robert et al., “Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors,” J Med Chem, 51(11): 3077-3080 (2008). [cited by applicant]
Sang et al., “FAM46B suppresses proliferation, migration and invasion of non-small cell lung cancer via ß-catenin/MMP7 signaling,” Transl Cancer Res, 8(4): 1497-1505 (2019). [cited by applicant]
Shah et al., “Synthesis of some new carboxanilides and amides of 8-methoxycoumarin-3-carboxylic acid as possible antifungal and antibacterial agents,” Journal of the Indian Chemical Society, vol. LXIV: 708-709 (1987). [cited by applicant]
Tam et al., “Discovery of a Small Molecule Inhibitor of The Wnt Pathway (sm04646) Delivered as an Inhaled Aerosol for The Treatment of Idiopathic Pulmonary Fibrosis (IPF),” American Journal of Respiratory and Critical C… [cited by applicant]
Wang et al., “Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening,” Eur J Med Chem, 129: 275-286 (2017). [cited by applicant]
Aros et al: “High-Throughput Drug screening Identifies a Potent Wnt Inhibitor that Promotes Airway Basal Stem Cell Homeostasis”, Cell Reports, vo1. 30, No. 7, Feb. 1, 2020, pp. 2055-2064+5. [cited by applicant]
Botham et al: “Dual Small-Molecule Targeting of Procaspase-3 Dramatically Enhances Zymogen Activation and Anticancer Activity”, Journal of the American Chemical Society, vol. 136, No. 4, Jan. 29, 2014, pp. 1312-1319. [cited by applicant]
Partial Supplementary European Search Report for EP Application No. 20905509.4 dated Jan. 2, 2024. [cited by applicant]
Zorn et al: “Self-Assembling Small Molecules Form Nanofibrils That Bind Procaspase-3 to Promote Activation”, Journal of the American Chemical Society, vol. 133, No. 49, Nov. 17, 2011, pp. 19630-19633. [cited by applicant]